Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Spriaso General Information
Spriaso has developed and received FDA approval for Tuxarin ER®, a long acting codeine/chlorpheniramine combination antitussive product. The company’s portfolio includes several proprietary CNS and GI disorder candidates that have completed proof-of-principle clinical studies and are expected to proceed to NDA filing. Products are available for out-license and protected by multiple patents. No active clinical trials are currently listed on ClinicalTrials.gov.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Salt Lake City, Utah
United States
United States
Drug Pipeline
codeine + antihistamine
CommercialKey Partnerships
Nexgen Pharma (co-development/manufacturing partner for Tuxarin ER®/Rinotuss12®)
Spriaso Funding
No funding data available
To view Spriaso's complete valuation and funding history, request access »